Vaccine Market Destined to Reach US$ 88.8 Billion (CAGR of 10.3%) During 2023-2028 - Latest Research Report

The latest report by IMARC Group, titled "Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028," offers a comprehensive analysis of the industry, which comprises insights on the global vaccine market. The report also includes competitor and regional analysis, and contemporary advancements in the global market.

The global vaccine market size reached US$ 49.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 88.8 Billion by 2028, exhibiting a growth rate (CAGR) of 10.3% during 2023-2028.

A vaccine is a biological preparation that stimulates the immune system to recognize and develop immunity against specific diseases or pathogens. It typically consists of weakened or killed microorganisms or parts of microorganisms, known as antigens, which trigger an immune response without causing the actual disease. When administered to individuals, vaccines prompt the production of antibodies and immune memory cells, providing protection against future infections by the targeted pathogen. Vaccination is a crucial aspect of preventive healthcare, playing a pivotal role in controlling and eradicating infectious diseases on a global scale.

Request Free Sample Report: https://www.imarcgroup.com/vaccine-market/requestsample

Global Vaccine Market Trends and Drivers:

The global vaccine market is witnessing robust growth, driven by the increasing prevalence of infectious diseases, such as influenza, measles, and meningitis. Outbreaks and epidemics highlight the urgent need for preventive measures, and governments and health organizations are investing in vaccination programs to curb the spread of these diseases, thereby boosting the vaccine market. Moreover, the ongoing focus on global health security and pandemic preparedness has brought vaccines to the forefront of public health strategies.

Recent events, such as the COVID-19 pandemic, have underscored the importance of rapid vaccine development, production, and distribution to combat emerging health threats. As a result, there is heightened investment in research and development, capacity building, and international collaborations to strengthen vaccine supply chains and enhance global vaccine accessibility.

By the IMARC Group, Some of the Top Competitive Landscape Operating in the Market are Given Below:

• Abbott Laboratories (NYSE: ABT)
• Astellas Pharma Inc. (OTCMKTS: ALPMY)
• AstraZeneca Plc (NASDAQ: AZN)
• Bharat Biotech International Limited
• Bavarian Nordic A/S (OTCMKTS: BVNRY)
• CSL Limited (OTCMKTS: CSLLY)
• Daiichi Sankyo Company, Limited (OTCMKTS: DSNKY)
• Emergent BioSolutions Inc. (NYSE: EBS)
• GlaxoSmithKline Plc (NYSE: GSK)
• Inovio Pharmaceuticals Inc. (NASDAQ: INO)
• Johnson & Johnson, Inc. (NYSE: JNJ)
• Merck & Co. Inc. (NYSE: MRK)
• Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
• Novavax Inc. (NASDAQ: NVAX)
• Panacea Biotec Ltd. (NSE: PANACEABIO)
• Pfizer Inc. (NYSE: PFE)
• Sanofi Pasteur SA (Sanofi SA) (NASDAQ: SNY)
• Serum Institute of India Pvt. Ltd.
• Takeda Pharmaceutical Company Limited (NYSE: TAK)

Explore the Full Report with Charts, Table of Contents, and List of Figures: https://www.imarcgroup.com/vaccine-market

Key Market Segmentation:

Breakup by Technology:

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others

Breakup by Patient Type:

• Paediatric
• Adult

Breakup by Indication:

• Bacterial Diseases
o Meningococcal Disease
o Pneumococcal Disease
o Diphtheria/Tetanus/Pertussis (DPT)
o Tuberculosis
o Haemophilus Influenzae (Hib)
o Typhoid
o Others
• Viral Diseases
o Hepatitis
o Influenza
o Human Papillomavirus (HPV)
o Measles/Mumps/Rubella (MMR)
o Rotavirus
o Herpes Zoster
o Varicella
o Japanese Encephalitis
o Rubella
o Polio
o Rabies
o Dengue
o Others

Breakup by Route of Administration:

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others

Breakup by Product Type:

• Multivalent Vaccine
• Monovalent Vaccine

Breakup by Treatment Type:

• Preventive Vaccine
• Therapeutic Vaccine

Breakup by End User:

• Hospitals
• Clinics
• Vaccination Centres
• Academic and Research Institutes
• Others

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Institutional Sales
• Others

Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the Report:

• Market Performance (2017-2022)
• Market Outlook (2023-2028)
• COVID-19 Impact on the Market
• Porter's Five Forces Analysis
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Explore the Most Recently Released Plant Setup Report:

• Bendable Concrete Manufacturing Plant Project Report 2023: https://www.imarcgroup.com/bendable-concrete-manufacturing-plant-project-report

• Bamboo Flooring Manufacturing Plant Project Report 2023: https://www.imarcgroup.com/bamboo-flooring-manufacturing-plant-project-report

• Carbon Monoxide Manufacturing Plant Project Report 2023: https://www.imarcgroup.com/carbon-monoxide-manufacturing-plant-project-report

• Compressed Stabilized Earth Block (CSEB) Manufacturing Plant Project Report 2023: https://www.imarcgroup.com/compressed-stabilized-earth-block-manufacturing-plant-project-report

• Hemp Concrete Manufacturing Plant Project Report 2023: https://www.imarcgroup.com/hemp-concrete-manufacturing-plant-project-report

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic, and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology, and novel processing methods are at the top of the company's expertise.

This release was published on openPR.